Form 4: Cytokinetics Director Wendell Wierenga Acquires Shares in Lieu of Cash Retainer

Director Wendell Wierenga acquired 162 shares of Cytokinetics Inc. common stock on April 15, 2025, through the Director Stock in lieu of Cash Retainer Program.

Summary

• On April 15, 2025, Wendell Wierenga, a director of Cytokinetics Inc., acquired 162 shares of common stock.
• The acquisition was made through the Director Stock in lieu of Cash Retainer Program.
• The price per share was $38.56.
• Following the transaction, Wierenga directly owns 24,848 shares of Cytokinetics Inc. common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares is generally a good sign, but the quantity is small and part of a standard compensation program.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Directors often receive stock as part of their compensation, aligning their interests with those of shareholders. This is a common practice in publicly traded companies.

Stakeholder Impact

• The acquisition of shares by a director can have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Cytokinetics, Director Stock, Wendell Wierenga, Share Acquisition, Form 4, Beneficial Ownership